antibody

Monocloncal Antibody DIPEN (Clone BC4)

MBS442010

0.1 mg

435 USD

monoclonal

mouse

nonconjugated

[BC-4]

western blot, ELISA, immunohistochemistry

Antibody

Monocloncal Antibody DIPEN (Clone BC4)

[Aggrecan, N-terminal neoepitope DIPEN]

[Aggrecan Antibody, N-terminal neoepitope DIPEN]

[Aggrecan; Aggrecan core protein; aggrecan core protein; large aggregating proteoglycan; cartilage-specific proteoglycan core protein; chondroitin sulfate proteoglycan core protein 1; aggrecan; Cartilage-specific proteoglycan core protein; CSPCP; Chondroitin sulfate proteoglycan core protein 1]

[ACAN; ACAN; AGC1; SEDK; AGCAN; CSPG1; MSK16; CSPGCP; AGC1; CSPG1; MSK16; CSPCP]

PGCA_HUMAN

Monoclonal

IgG1

[BC-4]

Mouse

Human, Rat, Guinea pig, Horse, Pig

721

Recognizes the N-terminal neoepitope sequence (. DIPEN) generated at the “MMP cleavage site” after MMP catabolism in the interglobular domain of aggrecan between amino acids . PEN341 and 342FFG.

Affinity purified on protein G

Liquid; PBS, no preservatives

The antibody is stable until the expiry date give on the label if stored at -20°C. Repeated freezing and thawing should be avoided. Aliquoting is recommended.

Western Blot (WB), Immunohistochemistry (IHC), ELISA

Western Blot:. Suggested dilution: 1:100. Detects a band of approximately 60 kDa. Immunohistochemistry:. This antibody should work in IHC on formalin-or paraformaldehyde-fixed paraffin embedded sections as well as either alcochol-fixed frozen sections or un-fixed snap-frozen sections.

Immunogen: DIPEN synthetic peptide conjugate. Myeloma: x63-Ag8.653. Light Chain Type: kappa

Technical Notes: Samples are usually deglycosylated using 0.01 Units Chondroitinase ABC (Sigma), 0.01 Units Keratanase (Seikagaku) and 0.0001 Units Keratanase II (Seikagaku) per 10ug S-GAG of non-deglycosylated aggrecan for optimal epitope recognition in SDS-PAGE and immunohistochemistry (1, 2).

Antibodies to Aggrecan

This metabolite usually remains in the tissue complexed to hyaluronan but with extensive cartilage catabolism it may be released from the tissue.

22209083

AAH36445.1

P16112

Degradation Of The Extracellular Matrix Pathway (576263); Disease Pathway (530764); ECM Proteoglycans Pathway (833812); Endochondral Ossification Pathway (198812); Extracellular Matrix Organization Pathway (576262); Glycosaminoglycan Metabolism Pathway (645297); Keratan Sulfate Biosynthesis Pathway (645302); Keratan Sulfate Degradation Pathway (645303); Keratan Sulfate/keratin Metabolism Pathway (645301); MPS I - Hurler Syndrome Pathway (685537)

This gene is a member of the aggrecan/versican proteoglycan family. The encoded protein is an integral part of the extracellular matrix in cartilagenous tissue and it withstands compression in cartilage. Mutations in this gene may be involved in skeletal dysplasia and spinal degeneration. Multiple alternatively spliced transcript variants that encode different protein isoforms have been observed in this gene. [provided by RefSeq, Jul 2008]

Function: This proteoglycan is a major component of extracellular matrix of cartilagenous tissues. A major function of this protein is to resist compression in cartilage. It binds avidly to hyaluronic acid via an N-terminal globular region. Subunit structure: Interacts with FBLN1 . By similarity. Interacts with COMP. Ref.11. Subcellular location: Secreted extracellular space extracellular matrix . By similarity. Tissue specificity: Restricted to cartilages. Ref.4. Developmental stage: Expression was detected in chondrocytes throughout the developing skeleton. Domain: Two globular domains, G1 and G2, comprise the N-terminus of the proteoglycan, while another globular region, G3, makes up the C-terminus. G1 contains Link domains and thus consists of three disulfide-bonded loop structures designated as the A, B, B' motifs. G2 is similar to G1. The keratan sulfate (KS) and the chondroitin sulfate (CS) attachment domains lie between G2 and G3. Post-translational modification: Contains mostly chondroitin sulfate, but also keratan sulfate chains, N-linked and O-linked oligosaccharides. The release of aggrecan fragments from articular cartilage into the synovial fluid at all stages of human osteoarthritis is the result of cleavage by aggrecanase. Involvement in disease: Spondyloepiphyseal dysplasia type Kimberley (SEDK) [MIM:608361]: Spondyloepiphyseal dysplasias are a heterogeneous group of congenital chondrodysplasias that specifically affect epiphyses and vertebrae. The autosomal dominant SEDK is associated with premature degenerative arthropathy.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.9Spondyloepimetaphyseal dysplasia aggrecan type (SEMD-ACAN) [MIM:612813]: A bone disease characterized by severe short stature, macrocephaly, severe midface hypoplasia, short neck, barrel chest and brachydactyly. The radiological findings comprise long bones with generalized irregular epiphyses with widened metaphyses, especially at the knees, platyspondyly, and multiple cervical-vertebral clefts.Note: The disease is caused by mutations affecting the gene represented in this entry.Osteochondritis dissecans short stature and early-onset osteoarthritis (OD) [MIM:165800]: A type of osteochondritis defined as a separation of cartilage and subchondral bone from the surrounding tissue, primarily affecting the knee, ankle and elbow joints. It is clinically characterized by multiple osteochondritic lesions in knees and/or hips and/or elbows, disproportionate short stature and early-onset osteoarthritis.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.13. Sequence similarities: Belongs to the aggrecan/versican proteoglycan family.Contains 1 C-type lectin domain.Contains 1 EGF-like domain.Contains 1 Ig-like V-type (immunoglobulin-like) domain.Contains 4 Link domains.Contains 1 Sushi (CCP/SCR) domain.

0.1 mg

435 USD